Originally published byEU-Startups
Telum Therapeutics, a Spanish biotechnology company, today announced the successful completion of an €18 million Series A financing to advance its lead program targeting hospital-acquired (HABP) and ventilator-associated bacterial pneumonia (VABP). AMR Action Fund led the financing round, with participation from new investor Inveready and continued support from existing investors Invivo Partners, CDTI with its […]
The post Telum Therapeutics raises €18 million to advance treatments for hospital-acquired infections appeared first on EU-Startups.
🌐
More news from European UnionEuropean Union
EUROPE
Related News
Why legal literacy is becoming startup currency
3d ago
In a volatile world, a consistent sustainability policy is critical
4d ago
Google DeepMind and A24 announce first-of-its-kind research partnership
3d ago
David Potter, the man who put Psion in the palm of your hand, logs off at 82
3d ago
NASA says it will isolate volunteers from the outside world for a year
3d ago